Form D · Biotechnology
Adventa Bioscience Inc.
Lodi, WI · CIK 0001897546
Offering snapshot reported Mar 15, 2022 · SEC filing
- Reported sold
- $410K Offering amount: $410K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Mar 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 15, 2022 | Initial | $410,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b, 4a5
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-437404
No Finders fees or sales commissions were given for this transaction
Source: Form D, filed Mar 15, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Chip Goodman | Director |
| William Jackson | Director |
| Peter Lamb | Executive |
| John Timothy Shorty | Director |
| Christopher Tracy | Executive |
| Steven Wynne | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
925 Development Drive
Lodi, WI, 53555
Lodi, WI, 53555